Home » Inex Says Enzon Ends Agreement on Marqibo Cancer Drug
Inex Says Enzon Ends Agreement on Marqibo Cancer Drug
March 17, 2005
Inex Pharmaceuticals Corp. has agreed to end a collaboration with Enzon Pharmaceuticals Inc. for developing the Marqibo cancer drug after U.S. regulators rejected accelerated approval for the medicine. Enzon, based in Bridgewater, New Jersey, will pay $5 million for shared development costs as part of the termination, Burnaby, British Columbia-based Inex said today in a statement. The companies entered an agreement in January 2004 to develop the injectable treatment for non-Hodgkin's lymphoma.
Bloomberg (http://www.bloomberg.com/apps/news?pid=10000082&sid=aNzfxzxlQLXc)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct